Extremely important positive changes in investment behavior have recently occurred for Amicus Therapeutics Inc (NASDAQ: FOLD): its longer term price trend turned up, the stock’s recent price rise disrupted its longer term downtrend, positive upside/downside volume developed, its shorter term price trend turned up, and the stock rose on very heavy volume.
Small negative changes in fundamentals have recently occurred for Amicus Therapeutics Inc (NASDAQ: FOLD): the stock’s power rating fell below 50.
In light of these very positive signals we are reviewing our current Overall Rating of F. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
FOLD’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to be a major Value Builder.
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Amicus Therapeutics has a neutral Power Rating of 42 but a very low Appreciation Score of 1, with the Lowest Value Trend Rating the result.
Recent Price Action
On 12/15/23, Amicus Therapeutics Inc (NASDAQ: FOLD) stock enjoyed a large increase of 2.2%, closing at $12.72. Moreover, exceptionally high trading volume at 264% of normal accompanied the advance. The stock has performed in line with the market over the last nine months and has risen 10.9% during the last week.
Be the first to comment